Erica A Brooks, | |
1321 First St W, Ahoskie, NC 27910-8842 | |
(252) 209-8932 | |
Not Available |
Full Name | Erica A Brooks |
---|---|
Gender | Female |
Speciality | Psychologist - Counseling |
Location | 1321 First St W, Ahoskie, North Carolina |
Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1003119603 | NPI | - | NPPES |
138A2 | Other | NC | BCBSNC |
6107194 | Medicaid | NC |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
103TC1900X | Psychologist - Counseling | 2526 (North Carolina) | Primary |
Mailing Address | Practice Location Address |
---|---|
Erica A Brooks, 1321 First St W, Ahoskie, NC 27910-8842 Ph: (252) 209-8932 | Erica A Brooks, 1321 First St W, Ahoskie, NC 27910-8842 Ph: (252) 209-8932 |
News Archive
When treating early-stage prostate cancer, intensity modulated radiation therapy (IMRT) spares the bladder significantly more from direct radiation when compared to 3-D conformal proton therapy (3D-CPT), but the amount of rectal sparing is similar with both treatments, according to a study released in the October issue of the International Journal for Radiation Oncology*Biology*Physics, the official journal of the American Society for Therapeutic Radiology and Oncology.
Expanding opportunities for immigrants to obtain legal residency and citizenship may be the best option to offer them better access to health care, according to an article published today by the RAND Corporation in the journal Health Affairs.
People with substance abuse disorders cost Medicaid hundreds of millions of dollars annually in medical care, suggesting that early interventions for substance abuse could not only improve outcomes but also save substantial amounts of money, according to a comprehensive study that examined records of nearly 150,000 people in six states.
European scientists recently discovered a novel therapy to treat a subgroup of patients with hereditary breast/ovarian cancer. Both the EU and the US have approved an accelerated procedure to market this promising new treatment with few side effects.
› Verified 3 days ago